A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1408 participants.

Also called NCT07919405

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,408 participants (planned count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07919405
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Denmark, Germany, Hungary, Italy, Japan, Netherlands, Poland, Puerto Rico, South Africa, South Korea, Spain, United Kingdom (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07919405. Randomized; quadruple masking; primary purpose treatment. Start 2026-11-11 (anticipated); primary completion 2028-06-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity
Acronym
REDEFINE
Condition
Hypertension
Condition
Obesity
Intervention (Drug)
CagriSema
Intervention (Drug)
Semaglutide
Intervention (Drug)
Cagrilintide
Intervention (Drug)
Placebo
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct07919405
Content hash
ac7d67baf47a9c11c377eb0a6bfad2a29bc20b84f28160e2eab672046b4c1e1e